secwatch.observer — SEC 8-K summary
======================================

Issuer:     SAB Biotherapeutics, Inc. (SABS)
CIK:        0001833214
Form:       8-K
Filed at:   2024-05-31T23:59:59+00:00
Accession:  0000950170-24-066856
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SAB Biotherapeutics CFO Michael King resigns effective June 4; Mark Conley appointed Interim CFO
--------------------------------------------------------------------------------

- CFO Michael King resigns effective June 4, 2024 to become CEO at private oncology company; will remain advisor through year-end.
- Mark Conley, current VP Finance, appointed Interim CFO; board launches formal search for permanent replacement.
- Conley's compensation unchanged under existing agreement: $303K base salary, bonus eligibility, and 250,000 stock options.
- Company confirms FY2024 outlook and upcoming Phase 1 topline data readout for lead candidate SAB-142.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1833214/000095017024066856/0000950170-24-066856-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1833214/000095017024066856/sabs-20240526.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-066856

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer